SCHEMBL6414962

SCHEMBL6414962

CC(C)(C)NC(=O)c1cc(Cl)cs1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.44
APEX1 P27695 1/20 0.44
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
ALDH1A1 P00352 2/20 0.39
KDM4E B2RXH2 1/20 0.39
GLA P06280 1/20 0.39
GAA P10253 1/20 0.39
HPGD P15428 1/20 0.39
MAPK1 P28482 1/20 0.39
ALPL P05186 1/20 0.38
TP53 P04637 1/20 0.38
MDM2 Q00987 1/20 0.38
LMNA P02545 1/20 0.37
ANO1 Q5XXA6 2/20 0.36
HTT P42858 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
MELK Q14680 1/20 0.35
CNR1 P21554 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL164456 0.80 ALDH1A1 (0.40) POLBAPEX1MEN1KMT2AALDH1A1
SCHEMBL163383 0.80 ALDH1A1 (0.40) POLBAPEX1MEN1KMT2AALDH1A1
SCHEMBL16142828 0.80 ALDH1A1 (0.59) POLBAPEX1MEN1KMT2AALDH1A1
SCHEMBL1665488 0.72
Hydrochloric Acid SCHEMBL10515653 0.72 SLC6A2 (0.54) ALDH1A1TP53SMN1; SMN2MELK
SCHEMBL19638255 0.72 CTPS1 (0.49) MEN1KMT2AALDH1A1KDM4EHPGD
SCHEMBL8633709 0.71 ALDH1A1 (0.41) MEN1KMT2AALDH1A1GAALMNA
Hydrochloric Acid SCHEMBL10515647 0.71 KDM4E (0.40) POLBMEN1KMT2AALDH1A1KDM4E
SCHEMBL788121 0.70
SCHEMBL1771045 0.70

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6936736-B2 Amide derivative SUMITOMO MANUFACTURING COMPANY LIMITED (JP) 2005-08-30 US disclosed
EP-1034783-B1 AMIDE DERIVATIVES FOR THE TREATMENT OF RETINAL NEURODEGENERATIVE DISORDERS SUMITOMO PHARMA (JP) 2004-12-15 EP disclosed
US-20020147204-A1 Amide derivative SUMITOMO PHARMACEUTICALS COMPANY, LIMITED 2002-10-10 US disclosed
US-6384033-B1 DRUGS FOR VISION DEFECTS SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2002-05-07 US disclosed
EP-1034783-A1 AMIDE DERIVATIVES SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2000-09-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020147204-A1 Amide derivative ALDH1A2, NR1H2, HDAC3 POLB 3216/4885APEX1 1777/4885MEN1 3899/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.